Telix Pharmaceuticals logs US$477M half-year revenue
- Telix Pharmaceuticals reported US$477 million in first-half group revenue, representing a 22% increase year-over-year.
- The Telix share price traded up at $17.50 following the announcement of a US$38 million profit after tax.
- Management stated that the company expects full-year revenue and other income to exceed US$1 billion while advancing late-stage therapeutic programmes.
Telix Pharmaceuticals (ASX:TLX) reported group revenue of US$477 million for the first half of 2026, representing a 22% increase year-over-year.
The company tracked in line with the upper end of its full-year guidance of US$950 million to US$970 million while improving its group gross margin to 55%.
“Our strengthened balance sheet is enabling increased investment in late-stage programmes, including ProstACT Global; market expansion opportunities within our precision medicine portfolio; and manufacturing and supply chain capabilities that differentiate Telix,” said Telix Managing Director and Group CEO Dr Christian Behrenbruch.
The company stated that its adjusted EBITDA reached US$52 million alongside a profit after tax of US$38 million, supported by a US$40 million non-refundable payment from a Regeneron collaboration.
Management stated that the business enters the second half with strong momentum, noting that following the announcement the Telix share price was up at $17.10.
The company completed a refinancing of its convertible bond structure by issuing US$600 million of new convertible bonds due 2031.
Telix reported a research and development investment of US$124 million and maintained a cash balance of US$252 million alongside positive operating cash flow of US$23 million as of June 30.
